Nanotechnology-based inhalation treatments for lung cancer: State of the art

Nanotechnology, Science and Applications

Volumn 8, Issue , 2015, Pages 55-66

  Ahmad, Javed ^a   Akhter, Sohail ^a,b   Rizwanullah, Md ^a   Amin, Saima ^a   Rahman, Mahfoozur ^c   Ahmad, Mohammad Zaki ^d   Rizvi, Moshahid Alam ^e   Kamal, Mohammad A ^f   Ahmad, Farhan Jalees ^a  

^a HAMDARD UNIVERSITY   (India)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c Abhilashi College of Pharmacy   (India)

^d NAJRAN UNIVERSITY   (Saudi Arabia)

^e JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^f KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Drug targeting; Inhalational chemotherapy; Lung cancer; Nanoparticles; Nanotoxicity

Indexed keywords

CARBON NANOTUBE; CELECOXIB; CISPLATIN; DENDRIMER; DOXORUBICIN; DRUG CARRIER; GOLD NANOPARTICLE; GRAPHENE; LIPOSOME; LOSARTAN; MAGNETIC NANOPARTICLE; NANOCOMPOSITE; NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; PACLITAXEL; POLYMERIC NANOPARTICLE; QUERCETIN; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; TELMISARTAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CARCINOGENICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG PENETRATION; HUMAN; HYPERTHERMIC THERAPY; LUNG CANCER; LUNG METASTASIS; MELANOMA; MICELLE; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; NANOPHARMACEUTICS; NANOTOXICOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 84947901093     PISSN: None     EISSN: 11778903     Source Type: Journal    
DOI: 10.2147/NSA.S49052     Document Type: Review

References (76)

1. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61(2): 91-112.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2): 69-90.
3. American Lung Association. Trends in Lung Cancer Morbidity and Mortality. Epidemiology and Statistics Unit, Research and Scientific Affairs. Available from: http: //www. lung. org/lung-disease/lung-cancer/learning-more-about-lung-cancer/understanding-lung-cancer/. Accessed February 28, 2013.
4. Ferlay J, Soerjomataram I, Ervik M, etal. GLOBOCAN 2012 v1. 0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base Number 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http: //globocan. iarc. fr. Accessed December 13, 2013.
5. Cochrane Database of systematic reviews. Chemotherapy can improve survival rates for nonsmall cell lung cancer. Available from: http: //summaries. cochrane. org/CD002139/chemotherapy-can-improve-survival-rates-for-non-small-cell-lung-cancer. Accessed February 28, 2013.
6. Longo DL. Approach to the patient with cancer. In: Fauci AS, Braunwald E, Issel-bacher KJ, etal, editors. Harrison's Principles of Internal Medicine. 18th ed. New York, NY: McGraw Hill; 2011: 493-499.
7. Komaki R, Cox JD. Moss Radiation Oncology: Rationale, Technique, Results. St Louis, MO: Mosby-Year Book; 1994.
8. National Canscer Institute. SEER Stat Fact Sheet: Lung and Bronchus (2002-2008). Available from: http: //seer. cancer. gov/statfacts/html/lungb. html. Accessed December 19, 2012.
9. Roa WH, Azarmi S, Al-Hallak MH, etal. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release. 2011;150: 49-55.
10. Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small. 2007; 3(8): 1341-1346.
11. Kumar A, Sahoo SK, Padhee K, etal. Review on solubility enhancement techniques for hydrophobic drugs. Int J Comprehensive Pharmacy. 2011;3(3): 1-7.
12. Tseng CL, Wu SY, Wang WH, etal. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials. 2008;29: 3014-3022.
13. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25: 563-570.
14. Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60: 863-875.
15. Akhter S, Amin S, Ahmad J, etal. Nanotechnology to combat multidrug resistance in cancer. Resistance to Targeted ABC Transporters in Cancer. Switzerland: Springer International Publishing; 2015: 245-272.
16. Akhter S, Ahmad I, Ahmad MZ, etal. Nanomedicines as cancer therapeutics: current status. Curr Cancer Drug Targets. 2013;13(4): 362-378.
17. Ramesh R. Nanoparticle-mediated gene delivery to the lung. Methods Mol Biol. 2008;434: 301-331.
18. Yuan D, Lv Y, Yao Y, etal. Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: a retrospective clinical study. Thorac Cancer. 2012;3(4): 341-347.
19. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392: 1-19.
20. Zhang LJ, Xing B, Wu J, Xu B, Fang XL. Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes. Pulm Pharmacol Ther. 2008;21: 239-246.
21. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4: 299-319.
22. Alipour S, Montaseri H, Tafaghodi M. Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery. Colloids Surf B Biointerfaces. 2010;81: 521-529.
23. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41: 189-207.
24. Schreier H, Gagne L, Bock T, etal. Physicochemical properties and in vitro toxicity of cationic liposome cDNA complexes. Pharm Acta Helv. 1997;72(4): 215-223.
25. Kataoka K, Matsumoto T, Yokoyama M, etal. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release. 2000;64: 143-153.
26. Kwon G, Naito M, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Block copolymer micelles for drug delivery: loading and release of doxorubicin. J Control Release. 1997;48: 195-201.
27. Gill KK, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG5000-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm. 2011;79: 276-284.
28. Kalantarian P, Najafabadi AR, Haririan I, etal. Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery. Int J Nanomedicine. 2010;5: 763-770.
29. Tomoda K, Ohkoshia T, Hirotaa K, etal. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B Biointerfaces. 2009;71: 177-182.
30. Godugu C, Patel AR, Doddapaneni R, Marepally S, Jackson T, Singh M. Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release. 2013;172: 86-95.
31. Choi SH, Byeon HJ, Choi JS, etal. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J Control Release. 2015;197: 199-207.
32. Azarmi S, Tao X, Chen H, etal. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm. 2006;319: 155-161.
33. Xie Y, Aillon KL, Cai S, etal. Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm. 2010;392: 156-163.
34. Subedi RK, Kang KW, Choi HK, etal. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci. 2009;37: 508-513.
35. Videira M, Almeida AJ, Fabra A. Preclinical evaluation of a pulmonary delivered paclitaxel loaded lipid nanocarrier antitumor effect. Nanomedicine. 2012;8: 1208-1215.
36. Videira MA, Botelho MF, Santos AC, Gouveia LF, DeLima JJ, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target. 2002;10: 607-613.
37. Hu LD, Jia Y, Ding W. Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Pharmazie. 2010;65: 585-587.
38. Jyoti K, Kaur K, Pandey RS, Jain UK, Chandra R, Madan J. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies. J Colloid Interface Sci. 2015;445: 219-230.
39. Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release. 2013;171(3): 349-357.
40. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release. 2010;144: 233-241.
41. Khan OF, Zaia EW, Jhunjhunwala S, etal. Dendrimer-inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature. Nano Lett. 2015;15(5): 3008-3016.
42. Kaminskas LM, McLeod VM, Ryan GM, etal. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release. 2014;183: 18-26.
43. Pankhurst QA, Connolly J, Jones SK, etal. Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys. 2003;36: R167.
44. Akhter S, Ahmad Z, Singh M, etal. Cancer targeted metallic nanoparticle: targeting overview, recent advancement and toxicity concern. Curr Pharm Des. 2011;17: 1834-1850.
45. Verma NK, Staunton KC, Satti A, etal. Magnetic core-shell nanoparticles for drug delivery by nebulization. J Nanobiotechnology. 2013;11: 1.
46. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1: 315-320.
47. Plank C, Scherer F, Rudolph C. Localized nucleic acid delivery: a discussion of selected methods. In: Schleef M, editor. DNA Pharmaceuticals. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co KGaA; 2005: 55-116.
48. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4): 338-344.
49. Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target. 2011;19(10): 900-914.
50. Okamoto H, Shiraki K, Yasuda R, Danjo K, Watanabe Y. Chitosan-interferon-β gene complex powder for inhalation treatment of lung metastasis in mice. J Control Release. 2011;150: 187-195.
51. Tseng CL, Wang TW, Dong GC, etal. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials. 2007;28: 3996-4005.
52. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials. 2009;30: 3476-3485.
53. Dames P, Gleich B, Flemmer A, etal. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol. 2007;2(8): 495-499.
54. Sadhukha T, Wiedmann TS, Panyam J. Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials. 2013;34(21): 5163-5171.
55. Shim G, Choi HW, Lee S, etal. Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes. Mol Ther. 2013;21(4): 816-824.
56. Bermudez E, Mangum JB, Wong BA, etal. Pulmonary responses of mice, rats, and hamsters to subchronic inhalation of ultrafine titanium dioxide particles. Toxicol Sci. 2004;77(2): 347-357.
57. Elder A, Gelein R, Finkelstein JN, Driscoll KE, Harkema J, Oberdorster G. Effects of subchronically inhaled carbon black in three species. I. Retention kinetics, lung inflammation, and histopathology. Toxicol Sci. 2005;88(2): 614-629.
58. Warheit DB, Webb TR, Reed KL. Pulmonary toxicity screening studies in male rats with TiO2 particulates substantially encapsulated with pyrogenically deposited, amorphous silica. Part Fibre Toxicol. 2006;3: 3.
59. Warheit DB, Webb TR, Reed KL, Frerichs S, Sayes CM. Pulmonary toxicity study in rats with three forms of ultrafine-TiO2 particles: differential responses related to surface properties. Toxicology. 2007; 230(1): 90-104.
60. Warheit DB, Webb TR, Sayes CM, Colvin VL, Reed KL. Pulmonary instillation studies with nanoscale TiO2 rods and dots in rats: toxicity is not dependent upon particle size and surface area. Toxicol Sci. 2006;91(1): 227-236.
61. Lam CW, James JT, McCluskey R, Hunter RL. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci. 2004;77(1): 126-134.
62. Mercer RR, Scabilloni J, Wang L, etal. Alteration of deposition pattern and pulmonary response as a result of improved dispersion of aspirated single-walled carbon nanotubes in a mouse model. Am J Physiol Lung Cell Mol Physiol. 2008;294(1): 87-97.
63. Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds GA, Webb TR. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci. 2004;77(1): 117-125.
64. Curtis J, Greenberg M, Kester J, Phillips S, Krieger G. Nanotechnology and nanotoxicology: a primer for clinicians. Toxicol Sci. 2006;25(4): 245-260.
65. Hagens WI, Oomen AG, de Jong WH, Cassee FR, Sips AJ. What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol. 2007;49(3): 217-229.
66. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3): 311-330.
67. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 2005;113(7): 823-839.
68. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol. 2007;150(5): 552-558.
69. Oberdorster G, Sharp Z, Atudorei V, etal. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol. 2004;16(6-7): 437-445.
70. Lanone S, Boczkowski J. Biomedical applications and potential health risks of nanomaterials: molecular mechanisms. Curr Mol Med. 2006;6(6): 651-663.
71. Badea I, Wettig S, Verrall R, Foldvari M. Topical non-invasive gene delivery using gemini nanoparticles in interferon-gamma-deficient mice. Eur J Pharm Biopharm. 2007;65(3): 414-422.
72. Fernandez L, Sua LF, Camargo R, Basante M, Gutierrez O, MunozJ. Evaluation of the pulmonary inflammatory response in murine biomodels exposed to modified titanium oxide (tio2-Modified). Biomedical Research. 2015;1(2): 3.
73. Garnett MC, Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup Med (Lond). 2006;56(5): 307-311.
74. Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev. 2006;58(14): 1460-1470.
75. Witzmann FA, Monteiro-Riviere NA. Multi-walled carbon nanotube exposure alters protein expression in human keratinocytes. Nanomedicine. 2006;2(3): 158-168.
76. Schins RP, Knaapen AM. Genotoxicity of poorly soluble particles. Inhal Toxicol. 2007;19(1): 189-198.